Philippe Cassier

25PUBLICATIONS
162CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jul 01, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|May 01, 2026
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study.

|Apr 01, 2026
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Capucine Baldini, Philippe A Cassier, Jean-Pierre Delord

|Mar 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Yonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist

|Feb 25, 2026
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.

Carlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos

Pageof 5

Frequent Collaborators

5 joint publications

Jean-Yves Blay

4 joint publications

Antoine Italiano

4 joint publications

Aurelien Marabelle

3 joint publications

Christophe Caux